UP!

CLBS $1.76   View long term graphs

Caladrius Biosciences
Type
Public
Traded as NASDAQ: CLBS
Industry Biopharmaceuticals
Founded 2006 (2006)
Headquarters New York City, New York, U.S.
Key people
David J. Mazzo (CEO)
Website caladrius.com

Caladrius Biosciences (NASDAQ: CLBS) is an American biopharmaceutical company active in the field of stem cell therapy and regenerative medicine, particularly (in 2012) of cardiovascular disease.

The company was founded in 1980 and was formerly known as Corniche Group Inc, Phase III Medical Inc and NeoStem, Inc. It is headquartered in New York City, New York.

In 2012 they started a phase 2 clinical trial of AMR-001 (NBS10), an autologous bone marrow derived cell therapy enriched for CD34+ cells, for Acute Myocardial Infarction. Initial results included a statistically significant mortality benefit. After the interim results reported in Nov 2014 the company clarified the changes to the study.

The cancer therapies (Melapuldencel-T and ovapuldencel-T) below are an autologous dendritic cell-based immunotherapy using the patients own dendritic cells and samples of their tumour to make dendritic cells aimed at the patients tumour antigens. This should activate T cells to attack the tumour.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS

Ratings

2016-05-14 Reiterated Rating Maxim Group Hold
2016-05-06 Reiterated Rating Maxim Group Hold
2016-04-30 Upgrade Rodman & Renshaw Buy
2016-04-29 Upgrade HC Wainwright Neutral to Buy $1.25
2016-04-19 Reiterated Rating Maxim Group Hold
2016-01-26 Reiterated Rating Aegis Buy
2016-01-08 Reiterated Rating Aegis Buy $2.00
2016-01-08 Downgrade HC Wainwright Buy to Neutral
2016-01-07 Downgrade Maxim Group Buy to Hold
2015-12-28 Reiterated Rating Maxim Group Buy $12.00 to $4.00
2015-12-22 Reiterated Rating Maxim Group Buy $12.00 to $4.00
2015-09-24 Reiterated Rating Maxim Group Buy
2015-09-24 Reiterated Rating WBB Securities Buy $7.00
2015-08-07 Downgrade Benchmark Co. Buy to Hold $12.00 to $2.00
2015-06-25 Reiterated Rating Maxim Group Buy
2015-05-06 Lower Price Target Benchmark Co. Buy $22.00 to $12.00
2015-04-30 Lower Price Target Maxim Group Buy $15.00 to $12.00
2015-04-06 Initiated Coverage MLV & Co. Buy $14.00
2015-01-09 Initiated Coverage Oppenheimer Outperform $10.00
2015-01-09 Initiated Coverage Oppenheimer Holdings Inc. Outperform $10.00
2015-01-06 Reiterated Rating Aegis Positive $21.00
2014-11-24 Reiterated Rating Aegis Buy
2014-11-18 Lower Price Target MLV & Co. Buy $17.00 to $14.00
2014-11-14 Initiated Coverage Maxim Group Buy $15.00
2014-09-18 Reiterated Rating WBB Securities Strong-Buy $27.00
2014-05-28 Initiated Coverage Benchmark Co. Buy $22.00
2014-05-12 Lower Price Target Aegis Buy $23.00 to $21.00
2014-01-02 Boost Price Target Aegis Buy $21.00 to $23.00
2016-05-14 Reiterated Rating Maxim Group Hold
2016-05-06 Reiterated Rating Maxim Group Hold
2016-04-30 Upgrade Rodman & Renshaw Buy
2016-04-29 Upgrade HC Wainwright Neutral to Buy $1.25
2016-04-19 Reiterated Rating Maxim Group Hold

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks

Comments